# Effects of Ubiquinol on Oxidized Low‐Density Lipoprotein in Prediabetic Patients: A Randomized, Double‐Blinded, Placebo‐Controlled Study

## TL;DR

This study found that ubiquinol may reduce oxidized LDL in prediabetic patients, but the effect was not significantly different from a placebo.

## Contribution

The study is the first to investigate ubiquinol's effect on oxLDL in prediabetic patients in a controlled trial.

## Key findings

- Ubiquinol supplementation led to a significant within-group reduction in oxLDL levels.
- Placebo group showed no significant change in oxLDL levels.
- No adverse events were reported during the 12-week study.

## Abstract

Oxidized low‐density lipoprotein (oxLDL) has emerged as a promising biomarker of oxidative burden and cardiovascular risk. This study is aimed at evaluating the effect of ubiquinol supplementation, a potent lipophilic antioxidant, on oxLDL levels in prediabetic patients.

This was a prospective, randomized, double‐blinded, placebo‐controlled pilot study of 20 adults with impaired fasting plasma glucose (FPG). Participants were randomized to receive either ubiquinol (100 mg/day) or placebo for 12 weeks. Plasma oxLDL levels were measured at baseline and Week 12.

After 12 weeks, the ubiquinol group demonstrated a significant within‐group reduction in plasma oxLDL compared with baseline (p = 0.049), whereas no significant change was observed in the placebo group (p = 0.237). No adverse events were reported.

Daily ubiquinol (100 mg/day) for 12 weeks was associated with a significant within‐group decrease in plasma oxLDL among prediabetic participants; however, the between‐group difference versus placebo was not significant.

Thai Clinical Trials Registry: TCTR20250512008